Cortexyme (CRTX) Competitors $1.45 +0.02 (+1.40%) As of 02/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesTrends CRTX vs. OMCL, HSTM, MDRX, CDTX, ALEC, IKT, IPHA, FATE, SLDB, and TILShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Omnicell (OMCL), HealthStream (HSTM), Veradigm (MDRX), Cidara Therapeutics (CDTX), Alector (ALEC), Inhibikase Therapeutics (IKT), Innate Pharma (IPHA), Fate Therapeutics (FATE), Solid Biosciences (SLDB), and Instil Bio (TIL). Cortexyme vs. Omnicell HealthStream Veradigm Cidara Therapeutics Alector Inhibikase Therapeutics Innate Pharma Fate Therapeutics Solid Biosciences Instil Bio Omnicell (NASDAQ:OMCL) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Do insiders & institutionals have more ownership in OMCL or CRTX? 97.7% of Omnicell shares are owned by institutional investors. Comparatively, 63.2% of Cortexyme shares are owned by institutional investors. 2.6% of Omnicell shares are owned by insiders. Comparatively, 27.9% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, OMCL or CRTX? Omnicell has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Does the media favor OMCL or CRTX? In the previous week, Omnicell had 7 more articles in the media than Cortexyme. MarketBeat recorded 7 mentions for Omnicell and 0 mentions for Cortexyme. Omnicell's average media sentiment score of 0.93 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the media. Company Overall Sentiment Omnicell Positive Cortexyme Neutral Is OMCL or CRTX more profitable? Omnicell has a net margin of 1.13% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 3.82% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets Omnicell1.13% 3.82% 2.07% Cortexyme N/A -70.96%-63.53% Which has stronger valuation & earnings, OMCL or CRTX? Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmnicell$1.11B1.65$12.53M$0.27147.12CortexymeN/AN/A-$89.94M-$2.97-0.49 Do analysts prefer OMCL or CRTX? Omnicell currently has a consensus target price of $52.33, suggesting a potential upside of 31.76%. Given Omnicell's stronger consensus rating and higher possible upside, equities analysts clearly believe Omnicell is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omnicell 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in OMCL or CRTX? Omnicell received 346 more outperform votes than Cortexyme when rated by MarketBeat users. Likewise, 66.93% of users gave Omnicell an outperform vote while only 64.44% of users gave Cortexyme an outperform vote. CompanyUnderperformOutperformOmnicellOutperform Votes50066.93% Underperform Votes24733.07% CortexymeOutperform Votes15464.44% Underperform Votes8535.56% SummaryOmnicell beats Cortexyme on 15 of the 17 factors compared between the two stocks. Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.72M$3.12B$5.78B$8.98BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-0.4930.1126.4618.82Price / SalesN/A412.67457.0180.76Price / CashN/A183.5344.0437.47Price / Book0.373.567.634.64Net Income-$89.94M-$71.72M$3.18B$245.69M7 Day Performance2.11%-2.45%-1.82%-2.63%1 Month Performance-12.65%0.36%0.22%-2.37%1 Year Performance7.41%-11.50%17.49%13.65% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.45+1.4%N/A+11.7%$43.72MN/A-0.4955OMCLOmnicell3.8271 of 5 stars$39.61-1.5%$52.33+32.1%+40.6%$1.83B$1.11B146.713,650HSTMHealthStream3.8951 of 5 stars$33.95+0.1%$31.50-7.2%+23.8%$1.03B$279.06M52.231,092MDRXVeradigm3.275 of 5 stars$5.35+1.9%$12.67+136.8%-36.1%$575.87MN/A0.008,000Analyst ForecastNews CoverageCDTXCidara Therapeutics3.917 of 5 stars$23.94+2.6%$32.20+34.5%+57.8%$168.78M$63.90M-0.9490ALECAlector4.0711 of 5 stars$1.70+1.8%$3.75+120.6%-70.7%$166.48M$97.06M-1.00270Gap UpIKTInhibikase Therapeutics1.6301 of 5 stars$2.35+5.4%$6.50+176.6%+43.0%$163.00M$260,000.00-0.886IPHAInnate Pharma3.0126 of 5 stars$1.94-0.5%$11.50+492.8%-13.1%$162.63M$66.71M0.00220News CoverageGap UpFATEFate Therapeutics4.2003 of 5 stars$1.42+11.8%$6.75+375.4%-78.1%$161.72M$63.53M-0.86550Gap UpHigh Trading VolumeSLDBSolid Biosciences4.0792 of 5 stars$4.03+2.3%$15.30+279.7%-40.6%$161.04M$8.09M-1.33100Analyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumeTILInstil Bio2.9421 of 5 stars$23.01-3.5%$114.00+395.4%+103.0%$150.26MN/A-1.99410News CoveragePositive News Related Companies and Tools Related Companies Omnicell Alternatives HealthStream Alternatives Veradigm Alternatives Cidara Therapeutics Alternatives Alector Alternatives Inhibikase Therapeutics Alternatives Innate Pharma Alternatives Fate Therapeutics Alternatives Solid Biosciences Alternatives Instil Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRTX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersHere’s how you could profit from Elon’s NVIDIA partnership"Elon's #1 AI Stock" SET TO SOAR Forget ChatGPT! Because Elon Musk's AI promises to be 100x more powerfu...Behind the Markets | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRTX Stock Alerts